CorMedix, Inc. (CRMD)
8.21
+0.21
(+2.62%)
USD |
NASDAQ |
Oct 28, 16:00
8.21
0.00 (0.00%)
After-Hours: 20:00
CorMedix Enterprise Value : 509.14M for Oct. 27, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 27, 2026 | 509.14M |
| October 26, 2026 | 504.48M |
| October 23, 2026 | 497.49M |
| October 22, 2026 | 516.90M |
| October 21, 2026 | 492.83M |
| October 20, 2026 | 475.74M |
| October 19, 2026 | 460.98M |
| October 16, 2026 | 451.66M |
| October 15, 2026 | 467.20M |
| October 14, 2026 | 461.76M |
| October 13, 2026 | 461.76M |
| October 12, 2026 | 467.20M |
| October 09, 2026 | 460.98M |
| October 08, 2026 | 456.32M |
| October 07, 2026 | 453.22M |
| October 06, 2026 | 453.22M |
| October 05, 2026 | 451.66M |
| October 02, 2026 | 446.23M |
| October 01, 2026 | 464.09M |
| September 30, 2026 | 485.84M |
| September 29, 2026 | 503.70M |
| September 28, 2026 | 500.59M |
| September 25, 2026 | 497.49M |
| September 24, 2026 | 491.27M |
| September 23, 2026 | 485.06M |
| Date | Value |
|---|---|
| September 22, 2026 | 492.05M |
| September 21, 2026 | 491.27M |
| September 18, 2026 | 487.39M |
| September 17, 2026 | 492.83M |
| September 16, 2026 | 495.16M |
| September 15, 2026 | 490.50M |
| September 14, 2026 | 500.59M |
| September 11, 2026 | 495.55M |
| September 10, 2026 | 506.03M |
| September 09, 2026 | 519.23M |
| September 08, 2026 | 523.12M |
| September 04, 2026 | 542.53M |
| September 03, 2026 | 545.64M |
| September 02, 2026 | 556.51M |
| September 01, 2026 | 538.65M |
| August 31, 2026 | 529.33M |
| August 28, 2026 | 532.44M |
| August 27, 2026 | 533.21M |
| August 26, 2026 | 539.43M |
| August 25, 2026 | 552.63M |
| August 24, 2026 | 530.88M |
| August 21, 2026 | 524.67M |
| August 20, 2026 | 527.00M |
| August 19, 2026 | 549.52M |
| August 18, 2026 | 522.34M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Filana Therapeutics, Inc. | -51.36M |
| Eloxx Pharmaceuticals, Inc. | -8.120M |
| Breakthrough Chemistry, Inc. | 0.241M |
| BioStem Technologies, Inc. | 20.64M |
| Cardiac Biotech Solutions, Inc. | 5.690M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 25.99M |
| Revenue (Quarterly) | 101.93M |
| Total Expenses (Quarterly) | 75.94M |
| EPS Diluted (Quarterly) | 0.281 |
| Gross Profit Margin (Quarterly) | 75.66% |
| Profit Margin (Quarterly) | 25.50% |
| Earnings Yield | 25.63% |
| Operating Earnings Yield | 28.92% |
| Normalized Earnings Yield | 26.82 |